Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability
Open accessThe DOI matches its Crossref record; 188 of the 191 references it cites were found in a registry or an index.
Abstract
Status epilepticus (SE) is an acute, life-threatening medical condition that requires immediate, effective therapy. Therefore, the acute care of prolonged seizures and SE is a constant challenge for healthcare professionals, in both the pre-hospital and the in-hospital settings. Benzodiazepines (BZDs) are the first-line treatment for SE worldwide due to their efficacy, tolerability, and rapid onset of action. Although all BZDs act as allosteric modulators at the inhibitory gamma-aminobutyric acid (GABA)A receptor, the individual agents have different efficacy profiles and pharmacokinetic and pharmacodynamic properties, some of which differ significantly. The conventional BZDs clonazepam, diazepam, lorazepam and midazolam differ mainly in their durations of action and available routes of administration. In addition to the common intravenous, intramuscular and rectal administrations that have long been established in the acute treatment of SE, other administration routes for BZDs—such as intranasal administration—have been developed in recent years, with some preparations already commercially available. Most recently, the intrapulmonary administration of BZDs via an inhaler has been investigated. This narrative review provides an overview of the current knowledge on the efficacy and tolerability of different BZDs, with a focus on different routes of administration and therapeutic specificities for different patient groups, and offers an outlook on potential future drug developments for the treatment of prolonged seizures and SE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Mean time from drug administration to cessation of status epilepticus (SE) in minutes is displayed for different delivery routes, based on literature research, as far as available (n.a. = not available). Intravenous (i.v.) administration showed the fastest onset of action with a latency of less than 3 min, followed by intranasal (i.n.) and intramuscular (i.m.) administration, as well as buccal and rectal delivery. Due to the heterogeneous patient populations and study settings, the displayed values should only serve as a basic guidance [48, 50, 51, 146, 186–190]. MDZ midazolam, LZP lorazepam, DZP diazepam, CZP clonazepam](https://figures.cochat.ai/paper-figures/7b44ab2840314fb286af9f300a0a85a9/benzodiazepines-in-the-management-of-seizures-and-status-epilepticus-a-review-of-figure-2.jpg)
![Fig. 3 Time from therapy administration to cessation of status epilepticus (SE) is displayed to help decide on the clinical use of different delivery routes for benzodiazepines in SE, based on published preparations and process times for drug administration via intravenous injection (i.v.), intramuscular injection (i.m.), rectal, intranasal (i.n.) and buccal administration [48]. For i.v. administration, it was assumed that no peripheral indwelling venous catheter had yet been established analogous to Silbergleit et al. [48]. MDZ midazolam, LZP lorazepam, DZP diazepam, CZP clonazepam](https://figures.cochat.ai/paper-figures/9a5a8394f39342a6908fa83a02f2e299/benzodiazepines-in-the-management-of-seizures-and-status-epilepticus-a-review-of-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pre-hospital benzodiazepine administration may be effective in controlling repetitive seizures or status epilepticus and avoid hospitalization 212,213 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [212]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Long-term BZD use may also be appropriate for medical conditions such as complex seizure disorders,42 spasticity,43,44 sleep disorders involving abnormal movements (e.g., rapid eye movement (REM) sleep behavior disorder, restless leg syndrome),45 and catatonia.46,47”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trinka, E., Cock, H., Hesdorffer, D., Rossetti, A. O., Scheffer, I. E., Shinnar, S., Shorvon, S., & Lowenstein, D. H. (2015) · Epilepsia · doi:10.1111/epi.13121 · Cited by 2,494 · cited 3×
“Typically, the start of SE treatment is based on t1, with the time limit being 5 min for generalized convulsive (tonic–clonic) SE, 10 min for complex focal SE (focal SE with impaired consciousness), and 10–15 min for absence SE [16].”
BackgroundA Comparison of Four Treatments for Generalized Convulsive Status Epilepticus
Treiman, D. M., Meyers, P. D., Walton, N. Y., Collins, J. F., Colling, C., Rowan, A. J., Handforth, A., Faught, E., Calabrese, V. P., Uthman, B. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809173391202 · Cited by 1,325 · cited 1×
“[47] in 1988, which demonstrated a superior efficacy of LZP over phenobarbital (PB) and at least equal efficacy to phenytoin (PHT ± DZP) as a first-line treatment for SE.”
BackgroundGlauser, T., Shinnar, S., Gloss, D., Alldredge, B., Arya, R., Bainbridge, J., Bare, M., Bleck, T., Dodson, W. E., Garrity, L., et al. (2016) · Epilepsy Currents · doi:10.5698/1535-7597-16.1.48 · Cited by 1,280 · cited 5×
“Therefore, even if widely used in Latin America and in many European countries, CZP is still not recommended by the latest European or American SE guidelines [38, 140].”
BackgroundInfluentialAlldredge, B. K., Gelb, A. M., Isaacs, S. M., Corry, M. D., Allen, F., Ulrich, S., Gottwald, M. D., O'Neil, N., Neuhaus, J. M., Segal, M. R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa002141 · Cited by 888 · cited 2×
“[22] conducted a large placebo-controlled trial, showing that LZP at a dose of 2 mg led to seizure termination more frequently than placebo or DZP following i.”
BackgroundMethodIt’s time to revise the definition of status epilepticus
Lowenstein, D. H., Bleck, T., & Macdonald, R. L. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb02000.x · Cited by 805 · cited 1×
“The 5-min time limit that usually marks the transition from a prolonged seizure to SE dates back to an operational definition proposed by Lowenstein in 1999, aimed at ensuring that patients receive treatment as soon as possible [17].”
BackgroundIntramuscular versus Intravenous Therapy for Prehospital Status Epilepticus
Silbergleit, R., Durkalski, V., Lowenstein, D., Conwit, R., Pancioli, A., Palesch, Y., & Barsan, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107494 · Cited by 744 · cited 3×
“LZP showed a similar rate of seizure cessation [52]; albeit, this particular randomized trial was underpowered and was based on a re-analysis of [48].”
BackgroundResultInfluentialClinical Pharmacokinetics of Diazepam
Mandelli, M., Tognoni, G., & Garattini, S. (1978) · Clinical Pharmacokinetics · doi:10.2165/00003088-197803010-00005 · Cited by 496 · cited 1×
“The half-life of DZP is 24–48 h due to an extended redistribution into the muscle and fat tissue after initial adsorption [90].”
BackgroundBetjemann, J. P., & Lowenstein, D. H. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00042-3 · Cited by 495
McIntyre, J., Robertson, S., Norris, E., Appleton, R., Whitehouse, W. P., Phillips, B., Martland, T., Berry, K., Collier, J., Smith, S., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66909-7 · Cited by 445 · cited 2×
“3 mg/kg) with regard to response rate (cessation of seizures) in paediatric patients in randomized, controlled trials [12, 75].”
BackgroundEFNS guideline on the management of status epilepticus in adults
Meierkord, H., Boon, P., Engelsen, B., Göcke, K., Shorvon, S., Tinuper, P., & Holtkamp, M. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02917.x · Cited by 433 · cited 1×
“Therefore, even if widely used in Latin America and in many European countries, CZP is still not recommended by the latest European or American SE guidelines [38, 140].”
Background
Research works printed but not linked: 9
- Rosenow F. Status epilepticus im Erwachsenenalter. In: Diener HC, Weimar C, editors. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme Verlag; 2012.
- Singhi S, Murthy A, Singhi P, Jayashree M. Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. J Child Neurol. 2002;17(2):106–10. · DOI · Paper page
- Lahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ. 2000;321(7253):83–6. · DOI · Paper page
- Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav. 2004;5(2):253–5. · DOI · Paper page
- Kutlu NO, Dogrul M, Yakinci C, Soylu H. Buccal midazolam for treatment of prolonged seizures in children. Brain Dev. 2003;25(4):275–8. · DOI
- Detyniecki K, Van Ess PJ, Sequeira DJ, Wheless JW, Meng TC, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters-a randomized, double-blind, placebo-controlled trial. Epilepsia. 2019;60(9):1797–808. · DOI · Paper page
- Bergamini L, Mutani R, Fariello R, Liboni W, Quattrocolo GL. Action du Ro 5 ⁄ 4023 dans le traitement des differentes formes d epilepsie. Paper given at the Rivotril Symposium, Marseilles, France. 1972.
- Bergamini L, Mutani R, Liboni W. Elektroenzephalographische und klinische Bewertung des neuen Benzodiazepin Ro 5 ⁄ 4023. EEG EMG. 1970;1:182–8.
- Tridon P, Weber M. Conduite du traitement des etats de mal epileptiques par le Ro. Sem Hop Paris. 1973;49:29.
Cited by
Developmental and epileptic encephalopathies
Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 158
“Acquired structural aetiologies include:”
Diagnosis and management of status epilepticus: improving the status quo
Gettings, J. V., Chafjiri, F. M. A., Patel, A. A., Shorvon, S. D., Goodkin, H. P., & Loddenkemper, T. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00430-7 · Cited by 83
Rossetti, A. O., Claassen, J., & Gaspard, N. (2023) · Intensive Care Medicine · doi:10.1007/s00134-023-07263-w · Cited by 78
Chowdhury, R., Bhuia, M. S., Hasan, M. S. A., Ansari, S. A., Ansari, I. A., Gurgel, A. P. A. D., Coutinho, H. D. M., & Islam, M. T. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105704 · Cited by 49
Established and emerging GABAA receptor pharmacotherapy for epilepsy
Richardson, R. J., Petrou, S., & Bryson, A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1341472 · Cited by 48
Metadata
- Authors
- Kienitz, R., Kay, L., Beuchat, I., Gelhard, S., von Brauchitsch, S., Mann, C., Lucaciu, A., Schäfer, J.-H., Siebenbrodt, K., Zöllner, J.-P., Schubert-Bast, S., Rosenow, F., Strzelczyk, A., & Willems, L. M.
- Affiliations
- Goethe University Frankfurt (DE)
- Corresponding author
- Strzelczyk, Adam
- ORCID
- Venue
- CNS Drugs
- Published
- 2022-08-16
- Volume
- 36
- Issue
- 9
- Pages
- 951-975
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC9477921
- OpenAlex
- W4291824793
- Cited by
- 139
- References
- 191
- Citations by year
- 2026: 33 · 2025: 42 · 2024: 37 · 2023: 24 · 2022: 3
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by-nc)
- IRIS (submittedVersion, cc-by-nc)
- SERVAL (Université de Lausanne) (submittedVersion, cc-by-nc)
- Funders
- Johann Wolfgang Goethe-Universität, Frankfurt am Main
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- benzodiazepines, status epilepticus, prolonged seizures, route of administration, intranasal administration, intrapulmonary administration, clonazepam, diazepam, lorazepam, midazolam, GABAA receptor, pharmacokinetics, pharmacodynamics, efficacy, tolerability, anticonvulsant therapy
- MeSH terms
- Anticonvulsants, Benzodiazepines, Clonazepam, Diazepam, gamma-Aminobutyric Acid, Humans, Lorazepam, Midazolam, Seizures, Status Epilepticus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability. https://app.cochat.ai/papers/10.1007/s40263-022-00940-2
- The paper
- Kienitz, R., Kay, L., Beuchat, I., Gelhard, S., von Brauchitsch, S., Mann, C., Lucaciu, A., Schäfer, J.-H., Siebenbrodt, K., Zöllner, J.-P., Schubert-Bast, S., Rosenow, F., Strzelczyk, A., & Willems, L. M. (2022). Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability. CNS Drugs. https://doi.org/10.1007/s40263-022-00940-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.